Theravance Biopharma and Mylan announced that the U.S. Food and Drug Administration (FDA) has accepted the companies’ recently submitted New Drug Application (NDA) for revefenacin (TD-4208) for review.     If approved, revefenacin would be the first once-daily, nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 13, 2018.   “The acceptan...